Local control after craniospinal irradiation, intensity‐modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma
Authors:
- Arnold C. PaulinoAPArnold C. Paulino
- Michael SouthMSMichael South
- M. Fatih OkcuMOM. Fatih Okcu
Open Access
Abstract
BACKGROUND: The current study was conducted to determine whether the use of cochlear‐sparing intensity‐modulated radiotherapy (IMRT) boost results in excess local failures in children with medulloblastoma.METHODS: Fifty children with a median age of 7.8 years underwent resection, craniospinal irradiation (CSI), IMRT posterior fossa (PF) and/or tumor bed (TB) boost, and cisplatin‐based chemotherapy for medulloblastoma. For standard‐risk patients, the CSI dose was 18 to 23.4 grays (Gy) and was followed either by an IMRT PF boost to 36 Gy and a TB boost of 54 to 55.8 Gy (n = 29) or by an IMRT TB boost to 55.8 Gy (n = 4). For high‐risk patients, the CSI dose was 36 to 39.6 Gy followed by an IMRT PF boost to 54 to 55.8 Gy (n = 8), an IMRT PF boost to 45 Gy and a TB boost to 55.8 Gy (n = 2), or an IMRT TB boost to 55.8 Gy (n = 7). For the TB boost, a 2‐cm margin around the surgical bed was treated in most patients.RESULTS: The 5‐year overall and progression‐free survival rates (±standard deviation) were 72% ± 6.6% and 68.3% ± 6.8%, respectively, for all patients; 77.8% ± 7.4% and 75.1% ± 7.6%, respectively, for standard‐risk patients; and 60.8% ± 12.8% and 55.4% ± 12.8%, respectively, for high‐risk patients. The 5‐year PF control rate was 90.5% ± 4.6%. TB failures occurred in 3 patients (including 2 patients who had distant failure), whereas an isolated non‐TB PF failure occurred in 1 patient.CONCLUSIONS: The use of IMRT was associated with excellent local control and did not result in excess PF failures outside of the TB. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 25 references indexed in Scilit:
- Ototoxicity After Intensity-Modulated Radiation Therapy and Cisplatin-Based Chemotherapy in Children With MedulloblastomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Online Quality Control, Hyperfractionated Radiotherapy Alone and Reduced Boost Volume for Standard Risk Medulloblastoma: Long-Term Results of MSFOP 98Journal of Clinical Oncology, 2009
- Supine Craniospinal Irradiation Using Intrafractional Junction Shifts and Field-in-Field Dose Shaping: Early Experience at Methodist HospitalInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Neuropsychological outcome following intensity‐modulated radiation therapy for pediatric medulloblastomaPediatric Blood & Cancer, 2008
- Endocrine Outcomes for Children With Embryonal Brain Tumors After Risk-Adapted Craniospinal and Conformal Primary-Site Irradiation and High-Dose Chemotherapy With Stem-Cell Rescue on the SJMB-96 TrialJournal of Clinical Oncology, 2008
- Multi-Institution Prospective Trial of Reduced-Dose Craniospinal Irradiation (23.4 Gy) Followed by Conformal Posterior Fossa (36 Gy) and Primary Site Irradiation (55.8 Gy) and Dose-Intensive Chemotherapy for Average-Risk MedulloblastomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children’s Oncology GroupJournal of neurosurgery. Pediatrics, 2006
- Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJournal of Clinical Oncology, 2006
- Patterns of Failure Using a Conformal Radiation Therapy Tumor Bed Boost for MedulloblastomaJournal of Clinical Oncology, 2003
- Preliminary results of conformal radiation therapy for medulloblastomaNeuro-Oncology, 1999